Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Search
Professor Richeldi treatment initiation
Leading pulmonologist Professor Richeldi discusses why early initiation of treatment in Idiopathic Pulmonary Fibrosis is important.
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Swine
Swine
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
Speak Up – Compliance Hotline
The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.
A life in a day: the reality of living with lung cancer
Within the initiative “A life in a day”, Anna-Maria spent 24 hours in the shoes of a lung cancer patient to better understand the patient experience.
Biberach
The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry
Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being
Uniting to stop rabies: a global and local endeavor
By collaborating together, we can stop rabies. Read how we are breaking down barriers through the power of partnerships to fight this deadly disease
Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
Supporting Fundappas
Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Improving lives by providing better access to treatments
Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
Partnership Boehringer Ingelheim Lifebit health data
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Building Lasting Partnerships for a Better Future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
Use of data: "A game changer for our industry"
Data is a game changer for the pharmaceutical industry and will shape our business. Listen to our podcast.
Understanding the language of dogs
Dogs are our best friends - however, communicating with them is not always easy. Let’s bust a few myths about our four-legged friends and how we can interact with them.
importance of velcro-like crackles in IPF diagnosis
Dr. Bonella, Rare Lung Disease Specialist, discusses the importance of accurate & early diagnosis inIdiopathic Pulmonary Fibrosis
Board of Managing Directors
Board of Managing Directors Boehringer Ingelheim